Section Arrow
Quote
SLN.NASDAQ
- Silence Therapeutics Plc
Quotes are at least 15-min delayed:2025/07/20 15:18 EDT
Regular Hours
Last
 6.04
-0.18 (-2.89%)
Day High 
6.295 
Prev. Close
6.22 
1-M High
6.6697 
Volume 
54.97K 
Bid
5.8
Ask
6.3
Day Low
5.92 
Open
6.22 
1-M Low
5.2236 
Market Cap 
293.77M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 6.18 
20-SMA 5.99 
50-SMA 5.33 
52-W High 22.465 
52-W Low 1.97 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.53/-1.53
Enterprise Value
293.77M
Balance Sheet
Book Value Per Share
-2.39
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
43.26M
Operating Revenue Per Share
0.76
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed：2025/07/20 15:18 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.